Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.60 |
| ▸ | BCR | P11274 | 1/20 | 0.60 |
| ▸ | PRKCA | P17252 | 1/20 | 0.60 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.60 |
| ▸ | CAMK2D | Q13557 | 5/20 | 0.56 |
| ▸ | CDK2 | P24941 | 4/20 | 0.56 |
| ▸ | CDK4 | P11802 | 1/20 | 0.56 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.54 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.54 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.54 |
| ▸ | PLK1 | P53350 | 1/20 | 0.51 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.47 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3247312 | 0.87 | NUDT1 (0.48) | NUDT1ABL1BCRPRKCAPRKCD | |
| SCHEMBL3252559 | 0.84 | CDK2 (0.57) | PRKCAPRKCDCDK2CDK4SMG1 | |
| SCHEMBL3246773 | 0.82 | NUDT1 (0.61) | NUDT1ABL1BCRPRKCAPRKCD | |
| SCHEMBL3605758 | 0.81 | FADS1 (0.62) | ABL1BCRPRKCAPRKCDCAMK2D | |
| SCHEMBL28201525 | 0.81 | ABL1 (0.63) | ABL1BCRPRKCAPRKCDCAMK2D | |
| SCHEMBL3247335 | 0.80 | EIF2AK2 (0.62) | ABL1BCRPRKCAPRKCDCAMK2D | |
| SCHEMBL3600187 | 0.80 | ABL1 (0.65) | ABL1BCRPRKCAPRKCDCAMK2D | |
| SCHEMBL3605722 | 0.80 | ABL1 (0.65) | ABL1BCRPRKCAPRKCDCAMK2D | |
| SCHEMBL3602654 | 0.78 | ABL1 (0.59) | ABL1BCRPRKCAPRKCDCAMK2D | |
| SCHEMBL3600200 | 0.78 | CDK2 (0.64) | ABL1BCRPRKCAPRKCDCAMK2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | claimed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | claimed |
| EP-1896470-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-03-12 | — | — | EP | claimed |
| WO-2006124863-A2 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2006-11-23 | — | — | WO | claimed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| EP-1896470-B1 | PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-05-26 | — | — | EP | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | TOYO BOSEKI KABUSHIKI KAISHA (JP) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300267-A1 | Compounds and Compositions as Protein Kinase Inhibitors | ERBB2, JAK2, AURKC | NUDT1 3955/4885ABL1 13/4885BCR 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.